The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes

Abstract

The presence of anti-ETAR antibodies is associated with a worse renal transplant function during the first 12months after transplantation. Including anti-ETAR antibodies in the diagnostics of renal transplant recipient immune status should be considered to provide comprehensive assessment of humoral alloimmunity.

Non-HLA Antibodies: Angiotensin II Type 1 Receptor (Anti-AT1R) and Endothelin-1 Type A Receptor (Anti-ETAR) Are Associated With Renal Allograft Injury and Graft Loss

“…It seems reasonable to consider whether predicting a patient's clinical outcome on the basis of HLA presensitization alone is sufficient. Our recent analysis showed that anti-HLA donor-specific antibodies had a significant disadvantageous influence on graft failure [13].…”

“…Non-HLA antibodies may also play an important role in the prediction of graft failure [2,3,13,17]. The detection of anti-AT1R antibodies seems to be an additional risk factor in finding renal recipients with higher immunological risk.…”

Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection

“…Others have reported that concomitant HLA and AT 1 R antibodies in renal and cardiac transplantation increased the risk of AMR and decreased graft survival [36, 46]. Endothelin type A receptor (ET A R) antibodies have also been reported in renal [47] and cardiac [39] transplantation. Antibodies against AT 1 R and ET A R have also been shown to be increased in lung allograft recipients with cystic fibrosis [48].…”

A Significant Role for Anti–Human Leukocyte Antigen Antibodies and Antibody-Mediated Rejection in the Biopsy-for-Cause Population

“…Our study shows that 80% of anti-HLA(þ) recipients who lost the transplant had anti-HLA Abs class II. Other potential donor targets include major histocompatibility complex class I-related chain A (MICA) [27] but most recently AT1R [28e30] and ETAR [31].…”